Basilea Pharmaceutica Balance Sheet Health
Financial Health criteria checks 5/6
Basilea Pharmaceutica has a total shareholder equity of CHF16.8M and total debt of CHF95.7M, which brings its debt-to-equity ratio to 570%. Its total assets and total liabilities are CHF188.7M and CHF171.9M respectively.
Key information
570.0%
Debt to equity ratio
CHF 95.68m
Debt
| Interest coverage ratio | n/a |
| Cash | CHF 62.96m |
| Equity | CHF 16.79m |
| Total liabilities | CHF 171.88m |
| Total assets | CHF 188.66m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0QNA's short term assets (CHF155.0M) exceed its short term liabilities (CHF37.8M).
Long Term Liabilities: 0QNA's short term assets (CHF155.0M) exceed its long term liabilities (CHF134.1M).
Debt to Equity History and Analysis
Debt Level: 0QNA's net debt to equity ratio (194.9%) is considered high.
Reducing Debt: 0QNA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 0QNA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 0QNA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 40.5% per year.